However, patients with longer hypertension duration (p < 0.001), those not using insulin (p = 0.002), and those with proteinuria (p = 0.003) appear to benefit more from SGLT2-i and RAS-i combination therapy (eFig. 2A). The gene discussed is SLC5A2; the disease is hypertensive disorder.